The Effect of Anti‐Scl‐70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis
Abstract
The objective of this study was to assess the predictive significance of anti‐Scl‐70 (anti‐topoisomerase I) antibodies, as determined by three different methods, for decline in forced vital capacity (FVC) within the first year of follow‐up in patients with systemic sclerosis (SSc)‐related interstitial lung disease (ILD).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 20, 2022
- Source ID
- 10.1002/acr2.11398
Entities
People
- Bochra Jandali
- Gloria A Salazar
- Julio Charles
- Katherine A. Terracina
- Marie Hudson
- Marka A. Lyons
- Marvin J. Fritzler
- Maureen D Mayes
- Rosa M. Estrada‐y‐martin
- Shervin Assassi
Organizations
- Congressionally Directed Medical Research Programs
- McGill University
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- University of Calgary
- University of Texas Health Science Center at Houston